RPN2 and cancer: RPN2 has also been revealed to contribute to the resistance of tumor cells to chemotherapeutic agents, including docetaxel and taxane, in animal models of breast (11) and ovarian (12) cancers, and in clinical studies of breast (11) and esophageal squamous cell carcinoma (13).